<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875261</url>
  </required_header>
  <id_info>
    <org_study_id>2018-004378-92</org_study_id>
    <nct_id>NCT03875261</nct_id>
  </id_info>
  <brief_title>Effect of Cannabinoid (THC / CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis</brief_title>
  <acronym>EdomTHC</acronym>
  <official_title>Effect of Cannabinoid (THC / CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Garcia Cinca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Clínic per la Recerca Biomedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Christian Dursteler</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the treatment of the symptoms of deep endometriosis with a cannabinoid
      derivate.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pressure threshold in hypogastrium that induces pain</measure>
    <time_frame>day 30 after treatment initiation</time_frame>
    <description>Pain threshold versus mechanical stimulation in hypogastrium (anterior central L2 dermatoma) measured in kPa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pressure threshold in dermatomes that induces pain</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Umbral of pain versus mechanical stimulation in dermatomes L2 anterior, L2 posterior, and T1 of the dominant upper extremity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature threshold in dermatomes that induces pain</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Umbral sensation versus thermal stimulus (cold heat) in anterior central L2 dermatomes, posterior central L2, and T1 of the dominant upper extremity. Measured in ºC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of the general pain</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Intensity of the general pain associated with endometriosis measured by a visual analogue scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression combined scale</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Anxiety and depression measured with the Scale of Anxiety and Hospital Depression Scale (HADS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Quality of Life measured through the EQ-5D-5L questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitivity</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Central sensitivity measured with the Central Sensitization Inventory (CSI) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive disorder measured by a list of words</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Cognitive disorder measured by a list of words (immediate memory and retention) and digits (attentional capacity) of the Wechsler Memory Scale (WMS-III).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>about sleep quality</measure>
    <time_frame>baseline, day 15, day 30 and day 45</time_frame>
    <description>Visual analogue scale 0-10 about sleep quality</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are treated with the investigational medical product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabinoid treatment</intervention_name>
    <description>Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between the ages of 18 and 40.

          -  Diagnosis of deep endometriosis after clinical suspicion and confirmation by imaging
             test.

          -  Pain with a score of 4 or more on a numerical visual scale of 11 levels (EVN 0-10) in
             the last 3 months (includes any type of pain associated with endometriosis:
             dysmenorrhea, dyspareunia, dyschezia, dysuria and / or pelvic pain).

          -  Women of childbearing age * should have a negative pregnancy test before inclusion in
             the study and should commit to using highly effective contraceptive methods (hormonal
             contraceptives, intrauterine device, intrauterine hormonal release systems, bilateral
             tubal occlusion, vasectomy the couple, barrier methods and sexual abstinence) during
             the entire duration of the study and up to 3 months after the end of it.

          -  Acceptance of participation in the study by signing the informed consent.

        Exclusion Criteria:

          -  Patients previously submitted to open abdominal surgery.

          -  History of cancer.

          -  Suspicion or diagnosis of endocrine, cardio-vascular or systemic pathology relevant.

          -  Pregnancy or anticipation of pregnancy up to 3 months after the end of the study.

          -  Current breastfeeding.

          -  Use of hormonal treatment (combined oral contraception, progestin in the 3 months
             prior to the study, GNRH analogs in the 6 months prior to the start of the study).

          -  Use of other analgesics different from those allowed in the study.

          -  Recreational or pharmacological use of cannabinoids.

          -  Hypersensitivity to cannabinoids or any of the exceptions.

          -  Known or suspected personal history, or family history of schizophrenia or other
             psychotic illnesses, severe personality disorder or other major psychiatric disorders.

          -  Patients with liver or kidney failure, severe cardiovascular disease and a history of
             epilepsy or recurrent seizures.

          -  Patients who use concomitant potent enzyme inducers of CYP3A4, such as rifampicin,
             carbamazepine, phenytoin, phenobarbital, and St. John's wort.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Dursteler, MD</last_name>
    <phone>+34.93.227.54.00</phone>
    <email>dursteler@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Dursteler, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>David Garcia Cinca</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

